For the year ending 2025-12-31, MDGL made $958,403K in revenue. -$288,284K in net income. Net profit margin of -30.08%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Product revenue, net | 958,403 | |||
| Cost of sales | 56,148 | |||
| Research and development | 388,525 | |||
| Selling, general and administrative | 813,827 | |||
| Total operating expenses | 1,258,500 | |||
| Loss from operations | -300,097 | |||
| Interest income | 37,364 | |||
| Interest expense | 22,309 | |||
| Loss on extinguishment of debt | -2,779 | |||
| Other expense, net | -463 | |||
| Net loss | -288,284 | |||
| Basic net loss per common share (in dollars per share) | -12.85 | |||
| Basic weighted average number of common shares outstanding (in shares) | 22,434,310 | |||
| Diluted net loss per common share (in dollars per share) | -12.85 | |||
| Diluted weighted average number of common shares outstanding (in shares) | 22,434,310 | |||
MADRIGAL PHARMACEUTICALS, INC. (MDGL)
MADRIGAL PHARMACEUTICALS, INC. (MDGL)